-5%
Linatin M is prescribed alongside proper diet and physical activity to enhance blood sugar control in adults with type 2 diabetes mellitus when the combined use of Linagliptin and Metformin Hydrochloride is appropriate.
Linagliptin acts as a DPP-4 (dipeptidyl peptidase-4) inhibitor, an enzyme responsible for breaking down incretin hormones such as GLP-1 and GIP. By inhibiting DPP-4, Linagliptin raises the levels of active incretins, thereby promoting glucose-dependent insulin secretion from pancreatic β-cells and reducing glucagon release from α-cells.
Metformin Hydrochloride is a biguanide oral antidiabetic agent that works by decreasing hepatic glucose production, limiting intestinal glucose absorption, and improving insulin sensitivity, which enhances peripheral glucose uptake and utilization. It helps lower both fasting and post-meal blood sugar levels and does not typically cause hypoglycemia.